The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...

Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

VRTX currently has a PEG ratio of 1.83. Another notable valuation metric for GILD is its P/B ratio of 6.97. The P/B ratio is used to compare a stock's market value with its book value, which is ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. While the S&P 500 has soared nearly 21% over the last 12 ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

VRTX currently has a PEG ratio of 1.83. Another notable valuation metric for GILD is its P/B ratio of 6.97. The P/B ratio is used to compare a stock's market value with its book value, which is ...